|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for PARVA |
 Gene summary |
| Basic gene Info. | Gene symbol | PARVA |
| Gene name | parvin, alpha | |
| Synonyms | CH-ILKBP|MXRA2 | |
| Cytomap | UCSC genome browser: 11p15.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_018222.4, | |
| Description | actopaxinalpha-parvincalponin-like integrin-linked kinase-binding proteinmatrix-remodeling-associated protein 2 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 608120 | |
| HGNC : HGNC | ||
| HPRD : 16283 | ||
| Protein | UniProt: Q9NVD7 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_PARVA | |
| BioGPS: 55742 | ||
| Pathway | NCI Pathway Interaction Database: PARVA | |
| KEGG: PARVA | ||
| REACTOME: PARVA | ||
| Pathway Commons: PARVA | ||
| Context | iHOP: PARVA | |
| ligand binding site mutation search in PubMed: PARVA | ||
| UCL Cancer Institute: PARVA | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for PARVA |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | R369 | S368F | SKCM | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for PARVA |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for PARVA from PDB |
| Top |
| Differential gene expression and gene-gene network for PARVA |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for PARVA |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0236969 | Substance-Related Disorders | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for PARVA |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of PARVA go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | III | Peptide ligand (ASP,ASP,LEU,ASP,ALA,LEU,LEU,ALA,ASP,LEU,GLU,SER) | 2vzd | A | R369 | III | Peptide ligand (MET,ASP,ASP,LEU,ASP,ALA,LEU,LEU,ALA,ASP,LEU,GLU,SER,THR) | 2vzd | B | R369 | III | Peptide ligand (ASN,LEU,SER,GLU,LEU,ASP,ARG,LEU,LEU,LEU,GLU,LEU,ASN,ALA,VAL) | 2vzg | B | R369 | III | Peptide ligand (ALA,THR,ARG,GLU,LEU,ASP,GLU,LEU,MET,ALA,SER,LEU,SER) | 2vzi | B | R369 |
| Top |
| Conservation information for LBS of PARVA |
| Multiple alignments for Q9NVD7 in multiple species |
| LBS | AA sequence | # species | Species | A249 | RHERDAFDTLF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | A249 | KGTRDAFDTLF | 1 | Caenorhabditis elegans | A257 | TLFDHAPDKLN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | A257 | TLFDYGPDKLA | 1 | Caenorhabditis elegans | D248 | GRHERDAFDTL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D248 | PKGTRDAFDTL | 1 | Caenorhabditis elegans | F250 | HERDAFDTLFD | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F250 | GTRDAFDTLFD | 1 | Caenorhabditis elegans | F365 | VLYNLFTKYRN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F365 | LLHLLFTKYKH | 1 | Caenorhabditis elegans | K260 | DHAPDKLNVVK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K260 | DYGPDKLAHVK | 1 | Caenorhabditis elegans | L253 | DAFDTLFDHAP | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L253 | DAFDTLFDYGP | 1 | Caenorhabditis elegans | R247 | SGRHERDAFDT | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R247 | APKGTRDAFDT | 1 | Caenorhabditis elegans | R369 | LFTKYRNVE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R369 | LFTKYKHI- | 1 | Caenorhabditis elegans | T252 | RDAFDTLFDHA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T252 | RDAFDTLFDYG | 1 | Caenorhabditis elegans | T267 | NVVKKTLITFV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T267 | AHVKTSLLAFC | 1 | Caenorhabditis elegans | V263 | PDKLNVVKKTL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V263 | PDKLAHVKTSL | 1 | Caenorhabditis elegans | V264 | DKLNVVKKTLI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V264 | DKLAHVKTSLL | 1 | Caenorhabditis elegans | Y362 | TLRVLYNLFTK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y362 | TLRLLHLLFTK | 1 | Caenorhabditis elegans |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |